A PHASE II TRIAL WITH BEVACIZUMAB AND IRINOTECAN FOR PATIENTS WITH PRIMARY BRAIN TUMORS AND PROGRESSION AFTER STANDARD THERAPY

被引：0
|
作者：
Moller, Soren [1 ]
Grunnet, Kirsten [1 ]
Hansen, Steinbjorn [2 ]
Schultz, Henrik [3 ]
Holmberg, Mats [4 ]
Sorensen, Morten M. [1 ]
Poulsen, Hans S. [1 ]
Lassen, Ulrik [1 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Odense Univ Hosp, Odense, Denmark
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Aalborg Univ Hosp, Aalborg, Denmark
来源：
NEURO-ONCOLOGY | 2010年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [41] Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer
    Spigel, D. R.
    Hainsworth, J. D.
    Yardley, D. A.
    Burris, H. A., III
    Farley, C.
    Zubkus, J.
    Meng, C.
    Murphy, P.
    Saez, R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [43] Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial
    Cramer, Christina K.
    Alphonse-Sullivan, Natalie
    Isom, Scott
    Metheny-Barlow, Linda J.
    Cummings, Tiffany L.
    Page, Brandi R.
    Brown, Doris R.
    Blackstock, Arthur W.
    Peiffer, Ann M.
    Strowd, Roy E.
    Rapp, Stephen
    Lesser, Glenn J.
    Shaw, Edward G.
    Chan, Michael D.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 337 - 344
  • [44] Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial
    Christina K. Cramer
    Natalie Alphonse-Sullivan
    Scott Isom
    Linda J. Metheny-Barlow
    Tiffany L. Cummings
    Brandi R. Page
    Doris R. Brown
    Arthur W. Blackstock
    Ann M. Peiffer
    Roy E. Strowd
    Stephen Rapp
    Glenn J. Lesser
    Edward G. Shaw
    Michael D. Chan
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 337 - 344
  • [45] Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
    Hobday, Timothy J.
    Qin, Rui
    Reidy-Lagunes, Diane
    Moore, Malcolm J.
    Strosberg, Jonathan
    Kaubisch, Andreas
    Shah, Manisha
    Kindler, Hedy Lee
    Lenz, Heinz-Josef
    Chen, Helen
    Erlichman, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (14) : 1551 - 1556
  • [46] Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial
    Xu, Jie
    Xie, Lu
    Sun, Xin
    Liu, Kuisheng
    Tang, Xiaodong
    Yan, Taiqiang
    Yang, Rongli
    Guo, Wei
    Gu, Jin
    ONCOLOGIST, 2021, 26 (07): : E1256 - E1262
  • [47] A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
    Campos, Susana
    Matulonis, Ursula
    Berlin, Suzanne
    Horowitz, Neil
    Liu, Joyce
    Krasner, Carolyn
    Hang, Lee
    Zarwan, Corrine
    Barry, William
    Colella, Tina
    Whalen, Christen
    Shoni, Melina
    Lundquist, Christine
    Birrer, Michael J.
    Penson, Richard
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1881 - 1890
  • [48] A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
    Susana Campos
    Ursula Matulonis
    Suzanne Berlin
    Neil Horowitz
    Joyce Liu
    Carolyn Krasner
    Lee Hang
    Corrine Zarwan
    William Barry
    Tina Colella
    Christen Whalen
    Melina Shoni
    Christine Lundquist
    Michael J. Birrer
    Richard Penson
    International Journal of Clinical Oncology, 2022, 27 : 1881 - 1890
  • [49] Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    Pitot, HC
    Wender, DB
    OConnell, MJ
    Schroeder, G
    Goldberg, RM
    Rubin, J
    Mailliard, JA
    Knost, JA
    Ghosh, C
    Kirschling, RJ
    Levitt, R
    Windschitl, HE
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) : 2910 - 2919
  • [50] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
12345